Orforglipron Guide
The Oral GLP-1 Pill With No Injection and No Fasting
Orforglipron is Eli Lilly's oral non-peptide GLP-1 agonist — no injection required, no fasting window before dosing. The Phase 3 ATTAIN trial demonstrated 14.7% mean weight loss at 36 weeks. This guide covers the mechanism, dosing schedule, side-effect profile, and expected FDA approval timeline.
What Is Orforglipron?
Orforglipron (LY3502970) is Eli Lilly's investigational oral GLP-1 receptor agonist. Unlike every other GLP-1 medication on the market, it's a non-peptide small molecule—meaning it doesn't need special formulation to survive the digestive system.
Why this matters: Current oral GLP-1 (Rybelsus) requires strict fasting and timing because the semaglutide peptide is fragile. Orforglipron's small molecule structure is more robust, allowing it to be taken with food at any time.
Administration: Once-daily oral pill, taken with or without food. No fasting, no timing restrictions, no injections.
Orforglipron vs Rybelsus
Key advantage: Rybelsus's strict requirements cause poor adherence. Orforglipron's flexibility could dramatically improve real-world effectiveness.
Key Biohacking Mechanics
Clinical Trial Results
Who Will Benefit Most?
Expected Dosing
Side Effects
Development Timeline
Why This Changes Everything
Vital Protocol FAQs
Guide FAQs
Complete guide to Orforglipron - Eli Lilly
Yes. Shotlee supports tracking Orforglipron doses, side effects, and health metrics. It is free to use.
Track Your Orforglipron Protocol in Shotlee
Free dose logging, side effect tracking, and health metric monitoring for your complete protocol.
📚References & sources
Latest on Orforglipron
New Weight Loss Pill Beats Oral Ozempic in Major Clinical Trial
A recent Phase 3 clinical trial indicates that orforglipron offers superior blood sugar control and weight loss compared to oral semaglutide, though side effects remain a consideration.
9 min read
Eli Lilly's Foundayo: A New Daily Pill Outperforming Oral Semaglutide
A groundbreaking Phase 3 trial reveals that Eli Lilly's new daily oral medication, orforglipron (Foundayo), demonstrates superior efficacy in lowering blood sugar and promoting weight loss compared to existing oral semaglutide treatments for individuals with Type 2 diabetes. This development marks a significant step forward in non-injectable peptide therapies for metabolic health.
6 min read
Wegovy Pill Launch: Why 80% of Patients Are Choosing Oral Semaglutide
The launch of the Wegovy pill marks a pivotal shift in obesity treatment. With 80% of new users being first-time patients, oral semaglutide is overcoming historical barriers to care.
9 min read